Twelve-Month Safety and Visual Acuity Results From a Feasibility Study of Intraocular, Epiretinal Radiation Therapy for the Treatment of Subfoveal CNV Secondary to Amd

Ávila, Marcos Pereira de; Farah, Michel Eid; Santos, Arturo; Kapran, Ziya; Duprat, João Paulo; Woodward, Benjamin W.; Nau, Jeffrey

doi:10.1097/iae.0b013e3181985915

Cited by 56 publications

(49 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At 12 months, all patients lost \3 lines and 5 of 17 patients in the 24 Gy group gained C3 lines. There were no adverse effects due to the radiation [61]. Mean change in VA at month 12 was ?10.3 letters in the 24 Gy and -1.0 letters in the 15 Gy cohort.…”

Section: Epimacular Brachytherapy (Embt) In Amdmentioning

confidence: 96%

Brachytherapy in Neovascular AMD

Grewal

Vajzovic

2015

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Neovascular age-related macular degeneration (AMD) has a complex pathophysiology, and although anti-VEGF therapy has been one of the most significant and successful advances, it is not effective for all patients with neovascular AMD. The potential role of radiation in the management of neovascular AMD has been suggested for several years. While previous work focused on the role of radiation alone, recent trials have evaluated the role of ionizing radiation as a synergistic treatment with anti-VEGF drugs, with endpoints being to reduce choroidal neovascular lesions faster, preserve visual acuity, and extend the treatment interval between injections. We review the current evidence available for the safety and efficacy of radiation in conjunction with anti-VEGF treatment for neovascular AMD delivered using three approaches-epimacular brachytherapy involving a pars plana vitrectomy (Vidion Neovista, Inc., Newark, CA, USA), episcleral brachytherapy without a pars plana vitrectomy (Salutaris Medical Devices, Tucson, AZ), and low-voltage stereotactic radiotherapy (IRay,

show abstract

Section: Epimacular Brachytherapy (Embt) In Amdmentioning

confidence: 96%

Brachytherapy in Neovascular AMD

Grewal

Vajzovic

2015

Curr Ophthalmol Rep

View full text Add to dashboard Cite

show abstract

“…Epimacular brachytherapy is undertaken as a one-off treatment and has been reported in Phase II trials. 2,3 These feasibility studies showed promising short-term results compared with anti-VEGF monotherapy, and there are two large, pivotal, randomized controlled trials under way-CABERNET and MERLOT. The former study investigates treatment-naive patients, the latter, patients who are already receiving anti-VEGF pharmacotherapy.…”

mentioning

confidence: 97%

Safety Testing of Epimacular Brachytherapy With Microperimetry and Indocyanine Green Angiography

Petrarca¹,

Richardson²,

Douiri³

et al. 2013

Retina

Self Cite

View full text Add to dashboard Cite

show abstract

“…While the first study demonstrated that a minimum dose of 24 Gy is required to achieve a therapeutic effect [14], the other study demonstrated the effect of brachytherapy combined with two injections of bevacizumab [13]. Radiation-induced complications were not reported, and the average increase in visual acuity was 8.9 letters.…”

mentioning

confidence: 97%

“…So far, only phase I/II studies for epiretinal brachytherapy in AMD using the VIDION system have been published [13,14]. While the first study demonstrated that a minimum dose of 24 Gy is required to achieve a therapeutic effect [14], the other study demonstrated the effect of brachytherapy combined with two injections of bevacizumab [13].…”

mentioning

confidence: 98%